Newsroom

September 15, 2026

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment

Innovative Medicine

September 14, 2026

Johnson & Johnson’s 2026 Oncology Care Index Finds Community Oncologists Confident in AI’s Promise, but Practical Adoption Still Lags

• Reported AI adoption in oncology has increased from 19% of healthcare providers across all practice settings in 2025 to 49% of community oncologists specifically in 2026 • Meanwhile use of advanced tools like predictive models remains low, at just 19%, revealing a gap between adoption and deeper implementation

Innovative Medicine

September 14, 2026

Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8%

Innovative Medicine

September 11, 2026

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Presidential Symposium to feature final overall survival results for first-line RYBREVANT plus chemotherapy in EGFR exon 20 insertion-mutated NSCLC Additional findings show low rates of key treatment-related events with subcutaneous RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) and prophylactic strategies

Innovative Medicine

September 9, 2026

Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

· 35+ abstracts demonstrate new findings across DARZALEX®, TECVAYLI® plus DARZALEX FASPRO®, CARVYKTI®, TALVEY®, and the investigational trispecific antibody ramantamig, highlighting the potential of early intervention with immune-based therapies to transform outcomes across the patient journey · With decades of leadership in multiple myeloma, Johnson & Johnson continues to drive innovation throughout the patient journey, from market-leading backbone therapies to next-generation immune-based approaches

Innovative Medicine

September 8, 2026

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

First presentation of pivotal Phase 3 CAPLYTA® data in adults with bipolar mania underscores the asset’s potential across mood disorders New SPRAVATO® analyses and schizophrenia research emphasize a focus on complex, high-burden neuropsychiatric conditions

Newsroom

Press releases

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson’s 2026 Oncology Care Index Finds Community Oncologists Confident in AI’s Promise, but Practical Adoption Still Lags

Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

You are now leaving jnj.com/innovativemedicine

Search Results

No Results

Newsroom

Press releases

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026

Johnson & Johnson’s 2026 Oncology Care Index Finds Community Oncologists Confident in AI’s Promise, but Practical Adoption Still Lags

Johnson & Johnson’s RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer

New overall survival data and treatment experience improvements reinforce the impact of RYBREVANT® (amivantamab-vmjw)-based regimens in EGFR-mutated lung cancer at WCLC 2026

Johnson & Johnson presents new data at IMS 2026 highlighting its industry-leading multiple myeloma portfolio, with the goal of advancing the potential for cure

Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026

You are now leaving jnj.com/innovativemedicine